Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
Mon, 11.08.2025
Eleving Group S.A.
Strong operational performance despite global economic uncertaintyOperational and Strategic HighlightsProfitability
Eleving Group ended the first six months of 2025 with stable growth in the revenue. The total revenue for the first six months of 2025 amounted to EUR 117.5 million, representing a 10.8% increase compared to the corresponding reportin [ … ]
Mon, 11.08.2025
ParTec AG
ParTec AG: ParTec AG files further patent infringement lawsuit against NVIDIA at UPC in Munich
Munich, August 11, 2025 – ParTec AG (ISIN: DE000A3E5A34 / WKN:A3E5A3) and its licensing agent BF exaQC AG have filed a further patent infringement lawsuit against NVIDIA Corporation at the Unified Patent Court (UPC) in Munich (see ad hoc announcement dat [ … ]
Mon, 11.08.2025
Salzgitter Aktiengesellschaft
Steel and steel-related activities impacted by challenges in the political and economic environment
Technology Business Unit and the participating investment in Aurubis AG bolster the result
P28 Performance Program generates an additional earnings contribution of € 48 million in the first half year
In the first half of 2025 that was characterized [ … ]
Mon, 11.08.2025
q.beyond AG
q.beyond increases EBITDA by 23% to € 2.7 million in Q2 2025
EBIT grows by € 1.2 million, consolidated net income by € 0.8 million
Forecast confirmed: significantly higher EBITDA and positive consolidated net income planned for 2025
Cologne, 11 August 2025. IT service provider q.beyond sustainably raised its earnings strength again in the second [ … ]
Mon, 11.08.2025
Northern Data AG
Northern Data Group Provides H1 2025 Financial Update
H1 2025 revenue of EUR 94.3 million, up 72% from H1 2024
H1 2025 Adjusted EBITDA of EUR 21.3 million, up 101% from H1 2024
Combined Cloud and Data Centers revenue of EUR 40.8 million in H1 2025, up 116% from H1 2024
Infrastructure upgrade effort commenced in Q2 remains ongoing and is resulti [ … ]
Mon, 11.08.2025
Northern Data AG
Northern Data and Elektron Energy execute non-binding term sheet agreement for the sale of Peak Mining
Frankfurt/Main – 11 August 2025 – Northern Data AG (ETR: NB2) (“Northern Data Group” or “Northern Data”), a leading provider of AI and High-Performance Computing (HPC) solutions, today confirms the execution of a non-binding, non-exclusive term sh [ … ]
Mon, 11.08.2025
Hypoport SE
Group Result H1/25
Hypoport delivers strong first half performance
Group revenue increases by 13% year-on-year to €305 million in H1/25
Gross profit grows by 14% year-on-year to €130 million
EBIT expands disproportionately by 94% to €16 million
Berlin, 11 August 2025 – Driven by a continued recovery in the private real estate financing bu [ … ]
Mon, 11.08.2025
Relief Therapeutics Holding SA
Relief Therapeutics Holding SA
/ Key word(s): Half Year Results
Relief Therapeutics Advances Publication of 2025 Half-Year Report
11.08.2025 / 07:00 CET/CEST
Relief Therapeutics Advances Publication of 2025 Half-Year Report
GENEVA (Aug. 11, 2025) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFTF, RLFTY) (Relie [ … ]
Mon, 11.08.2025
Nyxoah SA.
Nyxoah Announces Preliminary Results for the Second Quarter of 2025
Mont-Saint-Guibert, Belgium – August 11, 2025, 7:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA), today announced certain [ … ]
Mon, 11.08.2025
Newron Pharmaceuticals S.p.A.
Newron notes the publication of new preclinical research suggesting evenamide ameliorates schizophrenia-related dysfunction
New findings published in Neuropsychopharmacology are the first to demonstrate that evenamide targets the key site of schizophrenia pathology in the hippocampus, and so could be an ideal therapeutic agent for treatment of the [ … ]
